March 20, 2026

Stefan Pfister honored with Thomas and Doris Ammann Prize

Stefan Pfister honored with Thomas and Doris Ammann Prize

The University Children’s Hospital Zurich and the Thomas and Doris Ammann Foundation have awarded the Thomas and Doris Ammann Prize to Stefan Pfister, Director of the Hopp Children’s Cancer Center Heidelberg (KiTZ), Head of Department at the German Cancer Research Center (DKFZ), professor at the Heidelberg Medical Faculty of Heidelberg University, and pediatric oncologist at the Center for Pediatric and Adolescent Medicine at Heidelberg University Hospital (UKHD), with the Thomas and Doris Ammann Prize. They are honoring him for his pioneering contributions to the research and development of new diagnostic and therapeutic procedures for pediatric brain tumors. The prize, worth 200,000 Swiss francs, will be presented to Stefan Pfister on March 12, 2026, at the University Children’s Hospital Zurich.

The Hopp Children’s Cancer Center Heidelberg (KiTZ) is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD), and Heidelberg University (Uni HD).

The award recognizes Stefan Pfister’s pioneering contributions to research into childhood brain tumors. As director of the Hopp Children’s Cancer Center Heidelberg (KiTZ), head of department at the German Cancer Research Center (DKFZ), and pediatric oncologist at Heidelberg University Hospital (UKHD), he has made decisive advances in the molecular genetic characterization of brain tumors.. 

Stefan Pfister’s research led to the identification of several previously unknown genetic changes that contribute to the development of various types of brain tumors in children and adolescents. These include mutations that open up new therapeutic targets, as well as genetic changes that indicate a hereditary predisposition to cancer. His work has contributed significantly to a better understanding of the biological basis of childhood brain tumors and has enabled more precise, individually tailored therapies. 

Another milestone is the co-development of a new, molecular-based classification of brain tumors, which has now been incorporated into the international WHO classification. This is based on an AI-based method developed in Heidelberg for DNA methylation analysis. This method is now used worldwide to accurately diagnose childhood tumors and recommend the best possible treatment for each patient.

In 2016, Stefan Pfister initiated the founding of the Hopp Children’s Cancer Center Heidelberg (KiTZ). For the first time in Germany, KiTZ combines research and clinical care for children and adolescents with cancer under one roof, thus creating ideal conditions for the rapid transfer of scientific findings into innovative therapies. 

Pfister has headed the Department of Pediatric Neuro-Oncology at the DKFZ since 2012. He is a professor at Heidelberg Medical School and a pediatric oncologist at Heidelberg University Hospital. He is also involved in leading European research initiatives aimed at developing new, more effective and gentler cancer therapies for children. 

“This award is a great honor for me and the entire team,” says Stefan Pfister. “I would like to express my sincere thanks to the Thomas and Doris Ammann Foundation and the University Children’s Hospital Zurich for this outstanding recognition. The prize underscores the importance of international and interdisciplinary collaboration in pediatric cancer research. At the same time, it motivates us to continue to advance our research with all our strength and in the interests of our patients, in order to further improve the chances of recovery for children with cancer and reduce long-term consequences.”

Stefan Pfister’s numerous scientific awards include the German Cancer Award (2013), the Léopold Griffuel Award (2021), the Baden-Württemberg State Research Award (2022), and the Gottfried Wilhelm Leibniz Prize from the German Research Foundation (2023).

Thomas and Doris Ammann Foundation:

The Thomas and Doris Ammann Foundation was established in 2021 in accordance with the last will and testament of Zurich art dealer Doris Ammann. She left behind a high-caliber art collection, which originated with her brother Thomas Ammann, who died in 1993, and which she and her partner Georg Frei had steadily expanded since then. Doris Ammann stipulated in her will that the art collection be sold to support charitable causes. The foundation works with institutions close to Thomas and Doris Ammann to support projects in human medicine, art history, and education, and develops sustainable partnerships. 

An Image for this press release is available for download at:
https://www.kitz-heidelberg.de/fileadmin/media/kitz/news/2023/230525-Pfister-KiTZ.jpg

Caption: 
Scientist and pediatric oncologist Stefan Pfister is being honored today in Zurich with the Thomas and Doris Ammann Prize for his groundbreaking contributions to research into childhood brain tumors.

Note on use of images related to press releases 
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: “Source: Jutta Jung/DKFZ”.
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ’s Press Office (phone: ++49-(0)6221 42 2854, E-mail: presse@dkfz.de). Any commercial use is prohibited. 

Our latest News

discover more
European Biotech Act: bioRN brings Industry and Policymakers together

European Biotech Act: bioRN brings Industry and Policymakers together

How can Europe strengthen its global competitiveness in biotechnology? Heidelberg, July 7th: This question was at the heart of a high-level roundtable hosted by the bioRN Life Science Cluster with Member of the European Parliament Hildegard Bentele. Representatives from Ascendis Pharma, BD, PROGEN, Novaliq, BASF Agricultural Solutions, PEPperPRINT, Evotec and Isenbruck Bösl Hörschler joined the […]

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp